The Business Research Company’s report on the Pleural Diseases Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
Which emerging drivers are set to accelerate the growth of the pleural diseases market further?
The increasing prevalence of infectious diseases are expected to drive the growth of the pleural diseases market going forward. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites. Environmental changes to human behavior and advancements in global travel influence the increasing prevalence of infectious diseases. Infectious diseases such as bacterial pneumonia, tuberculosis, or viral infections can cause pleural disease by triggering inflammation, infection, or fluid accumulation in the pleural cavity. For instance, in January 2023, according to the National Library of Medicine, a US-based medical library for research and information, infectious diseases account for over 52 million deaths annually, placing half of the global population at risk. Further, each year, approximately 14 million children under the age of five die, with 70% of these deaths attributed to diseases that could be prevented through vaccination. Therefore, the increasing prevalence of infectious diseases drives the growth of the pleural diseases market.
Access Your Free Sample of the Global Pleural Diseases Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22099&type=smp
What are the key factors influencing the forecasted market size of the pleural diseases industry?
The pleural diseases market size has grown strongly in recent years. It will grow from $4.86 billion in 2024 to $5.23 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to rising incidence of pleural effusion, growing awareness about pleural diseases, increasing focus on early diagnosis, growing number of healthcare facilities, and rising number of pleural disease clinical trials.
The pleural diseases market size is expected to see strong growth in the next few years. It will grow to $6.94 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to rise in the prevalence of pleural diseases, rise in the aging population, increasing number of occupational hazards, rise in the number of clinical trials, and growing number of diagnostic centers. Major trends in the forecast period include advancements in diagnostics, advancements in diagnostic tools, adoption of minimally invasive procedures, improved drug development, and telemedicine adoption.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22099&type=smp
Who are the leading competitors in the pleural diseases market?
Major companies operating in the pleural diseases market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, GSK plc, Astrazeneca plc, Koninklijke Philips N.V., Becton Dickinson and Company, Boehringer Ingelheim International GmbH, Sanofi SA, Penn Medicine, Henry Ford Health, Dragerwerk AG, Emory Healthcare, Boston Medical Center, Cook Medical, WakeMed, Weill Cornell Medicine, Fox Chase Cancer Center, B. Braun SE, Bicakcilar, Redax S.p.a, Rocket Medical
Which emerging trends are set to transform the pleural diseases market landscape?
Major companies operating in the pleural diseases market are focusing on developing innovative treatment options, such as developing ready-to-use injectable treatments, to improve convenience, reduce preparation time, and minimize dosing errors. Ready-to-use injectable treatments are pre-formulated, pre-diluted medications that require no reconstitution or mixing before administration, ensuring accuracy, convenience, and reduced preparation time. For instance, in April 2024, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched PEMRYDI RTU, the first ready-to-use version of pemetrexed for injection. This helps people with pleural diseases by providing a convenient, ready-to-use treatment that eliminates the need for reconstitution or dilution, reduces preparation time, minimizes the risk of dosing errors, and improves access to effective therapy for conditions like malignant pleural mesothelioma.
How do different geographies compare in terms of market share and growth potential in the pleural diseases market?
North America was the largest region in the pleural diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pleural diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/pleural-diseases-global-market-report
Which major segments of the pleural diseases market are experiencing the fastest growth?
The pleural diseases market covered in this report is segmented –
1) By Disease Type: Pleurisy, Pleural Effusion, Pneumothelioma, Mesothelioma, Other Disease Types
2) By Treatment Modalities: Medications, Thoracentesis And Pleurodesis, Minimally Invasive Interventions, Surgical Interventions
3) By Diagnostic Tools: Imaging Techniques, Molecular Diagnostics, Thoracoscopy, Pleuroscopy
4) By End User: Hospitals And Clinics, Diagnostic Centers, Research And Academic Institutions
Subsegments:
1) By Pleurisy: Acute Pleurisy, Chronic Pleurisy, Infectious Pleurisy, Non-infectious Pleurisy
2) By Pleural Effusion: Transudative Pleural Effusion, Exudative Pleural Effusion, Malignant Pleural Effusion, Parapneumonic Pleural Effusion, Hemothorax, Chylothorax
3) By Pneumothelioma: Primary Pneumothelioma, Secondary Pneumothelioma (Metastatic), Localized Pneumothelioma, Diffuse Pneumothelioma
4) By Mesothelioma: Pleural Mesothelioma, Peritoneal Mesothelioma, Pericardial Mesothelioma, Testicular Mesothelioma
5) Other Disease Types: Pulmonary Embolism, Fibrothorax, Pneumothorax, Lung Cancer, Tuberculosis-Related Pleural Disease, Sarcoidosis
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22099
How is the pleural diseases market defined, and what are its core characteristics?
Pleural diseases refer to a group of conditions that affect the pleura, which is the double-layered membrane surrounding the lungs. These diseases can involve inflammation, infection, or other pathological pleural changes. Pleural diseases cause chest pain, shortness of breath, coughing, and difficulty breathing and are often diagnosed with imaging tests such as chest X-rays or CT scans.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
